2. Signaling Pathways
  3. Epigenetics
    Metabolic Enzyme/Protease
  4. Methionine Adenosyltransferase (MAT)

Methionine Adenosyltransferase (MAT)

S-adenosylmethionine Synthetase

Methionine adenosyltransferases (MATs), also known as S-Adenosylmethionine synthetase, are essential enzymes for life as they catalyzes the synthesis of one of the most important and pivotal biological molecules, S-adenosyl-methionine. S-adenosyl-methionine is the biological methyl donor required for a plethora of reactions within the cell.Mammalian systems express two genes, MAT1A and MAT2A, which encode for MATα1 and MATα2, the catalytic subunits of the MAT isoenzymes, respectively. A third gene MAT2B, encodes a regulatory subunit known as MATβ which controls the activity of MATα2. MAT1A, which is mainly expressed in hepatocytes, maintains the differentiated state of these cells, whilst MAT2A and MAT2B are expressed in extrahepatic tissues as well as non-parenchymal cells of the liver (e.g., hepatic stellate and Kupffer cells).

Methionine Adenosyltransferase (MAT) Related Products (41):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170503
    MAT2A-IN-20
    		Inhibitor
    MAT2A-IN-20 (Compound A49) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC50 ≤50 nM. MAT2A-IN-20 inhibits human UGT1A1 with an IC50 of 28.45 μM. MAT2A-IN-20 exhibits antitumor in mouse models.
    MAT2A-IN-20
  • HY-144184
    MAT2A-IN-6
    		Inhibitor
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18).
    MAT2A-IN-6
  • HY-144185
    MAT2A-IN-7
    		Inhibitor
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24).
    MAT2A-IN-7
  • HY-170905S
    MAT2A-IN-22
    		Inhibitor
    MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
    MAT2A-IN-22
  • HY-168445
    MAT2A-IN-21
    		Inhibitor
    MAT2A-IN-21 (compound 28) is a potent methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 49 nM. MAT2A-IN-21 selectivity inhibits MTAP-deficient cancer cells.
    MAT2A-IN-21
  • HY-170502
    MAT2A-IN-19
    		Inhibitor
    MAT2A-IN-19 (Compound I-3) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC50 of 32.93 nM.
    MAT2A-IN-19
  • HY-162010
    MAT2A-IN-13
    		Inhibitor
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors research.
    MAT2A-IN-13
  • HY-173281
    MAT2A-IN-24
    		Inhibitor
    MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a). The IC50 value for the inhibition of MAT2a is 20 nM, and the IC50 value for the antiproliferative activity against HAP1MTAP–/– cells is 10 nM. MAT2A-IN-24 can be used in the research field of tumor diseases associated with MTAP deficiency.
    MAT2A-IN-24
  • HY-144181
    MAT2A-IN-5
    		Inhibitor
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1).
    MAT2A-IN-5
  • HY-155149
    MAT2A-IN-12
    		Inhibitor
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP-/- cell line).
    MAT2A-IN-12
  • HY-155148
    MAT2A-IN-11
    		Inhibitor
    MAT2A Allosteric inhibitor 1 (compound 5) is a MAT2A selective inhibitor of methionine adenosyltransferase (MAT) with an IC50 of 6.8 nM.
    MAT2A-IN-11
  • HY-161298
    MAT2A-IN-15
    		Inhibitor
    MAT2A-IN-15 (compound 8) is an inhibitor of MAT2A.
    MAT2A-IN-15
  • HY-159156
    MAT2A inhibitor 6
    		Inhibitor
    MAT2A inhibitor 6 (Compound 3N-h) is a specific MAT2A inhibitor with oral activity and yellow fluorescence (IC50=26 nM), capable of visualizing MAT2A both in vitro and in vivo (λex = 430 nm, λem = 585 nm). MAT2A inhibitor 6 can induce apoptosis and has anticancer activity, which can be used in cancer research.
    MAT2A inhibitor 6
  • HY-149915
    MAT2A-IN-10
    		Inhibitor
    MAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC50 of 26 nM. MAT2A-IN-10 can be used for the research of cancer.
    MAT2A-IN-10
  • HY-144179
    MAT2A-IN-4
    		Inhibitor
    MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer.
    MAT2A-IN-4
  • HY-163656
    MAT2A inhibitor 5
    		Inhibitor 98.80%
    MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of MAT2A with the IC50 of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo.
    MAT2A inhibitor 5
  • HY-179622
    ZS34
    ZS34 is a potent, orally active, and selective MAT2A inhibitor with an IC50 of 13.7 nM, displaying minimal hERG and UGT1A1 liabilities. ZS34 selectively suppresses the growth of methylthioadenosine phosphorylase (MTAP)-deficient cancer cells by inhibiting SAM synthesis, reducing SDMA levels, and inducing DNA damage. ZS34 exhibits antitumor efficacy in a HCT116 MTAP-/- xenograft mouse model. ZS34 can be used for the research of MTAP-deficient cancer.
    ZS34
  • HY-170421
    MAT2A-IN-16
    		Inhibitor
    MAT2A-IN-16 is a MAT2A inhibitor and inhibits cell proliferation of MTAP-/- HCT-116 cells (IC50: 20 nM).
    MAT2A-IN-16
  • HY-108331R
    3-TYP (Standard)
    		Inhibitor
    3-TYP (Standard) is the analytical standard of 3-TYP (HY-108331). This product is intended for research and analytical applications. 3-TYP is an inhibitor of SIRT3 (IC50of 38 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases.
    3-TYP (Standard)
  • HY-181285
    MAT2A ligand 1
    		Inhibitor
    MAT2A ligand 1 is a MAT2A ligand inhibitor (IC50=29.5 nM) and PET tracer that crosses the blood-brain barrier. MAT2A ligand 1 enables non-invasive imaging of MAT2A-expressing tumors, with rapid tumor uptake equilibrium, a high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable to research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer.
    MAT2A ligand 1